Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 1;11(8):835-845.
doi: 10.1001/jamaoncol.2025.1340.

Body Mass Index, Physical Activity, and Subsequent Neoplasm Risk Among Childhood Cancer Survivors

Lenat Joffe  1   2 , Sedigheh Mirzaei  3 , Shalini Bhatia  3 , Himani Darji  3 , Kirsten K Ness  4 , Aron Onerup  4   5 , Elena J Ladas  6 , Cindy Im  7 , Philip J Lupo  8 , Kevin C Oeffinger  9 , Danielle Novetsky Friedman  10 , Rebecca M Howell  11 , Miriam R Conces  12 , Michael A Arnold  13   14 , Gregory T Armstrong  4 , Joseph P Neglia  7 , Yutaka Yasui  4 , Nina S Kadan-Lottick  15   16 , Lucie M Turcotte  7
Affiliations

Body Mass Index, Physical Activity, and Subsequent Neoplasm Risk Among Childhood Cancer Survivors

Lenat Joffe et al. JAMA Oncol. .

Abstract

Importance: High body mass index (BMI) and low physical activity levels are risk factors for adult-onset cancers. Limited data exist on their relationship with subsequent neoplasms among childhood cancer survivors.

Objective: To evaluate associations between time-varying BMI/physical activity and subsequent neoplasm risk among childhood cancer survivors.

Design, setting, and participants: This retrospective cohort analysis included 5-year childhood cancer survivors diagnosed younger than 21 years of age between 1970 and 1999, enrolled in the Childhood Cancer Survivor Study (CCSS), with follow-up through September 2019 at pediatric tertiary care hospitals in the US and Canada. The data analysis was performed between March 2021 and July 2024.

Exposures: Self-reported time-varying BMI and maximum reported physical activity (metabolic equivalent of task h/wk [MET-h/wk]) before any subsequent neoplasm development; first assessed at cohort entry and up to 6 times thereafter.

Main outcomes and measures: Cumulative incidence by physical activity level and relative rates (RRs) by physical activity and time-varying BMI categories, adjusted for demographic and clinical variables, were estimated for any, subtype (hematologic, solid organ, central nervous system [CNS], skin), and specific (breast, thyroid, colorectal, meningioma) subsequent neoplasms using piecewise exponential models.

Results: Of 25 658 enrolled CCSS participants, 22 716 had BMI data before subsequent neoplasm development and met eligibility criteria for this study (46.3% female; median [range] attained age, 33.7 [5.7-67.3 years]). Among 22 716 survivors, 2554 subsequent neoplasms occurred among 2156 individuals (56.7% female; median [range] age at subsequent neoplasm diagnosis, 37.4 [13.7-63.3] years). Survivors reporting lower physical activity had higher 30-year subsequent neoplasm cumulative incidence: 18.6% (95% CI, 17.0-20.3) for 0 MET-h/wk vs 10.9% (95% CI, 9.9-12.1) for 15-21 MET-h/wk. Obese BMI was associated with increased incidence rates of solid organ (RR, 1.22; 95% CI, 1.01-1.46), CNS (RR, 1.47; 95% CI, 1.12-1.95), and skin (RR, 1.30; 95% CI, 1.13-1.50) subsequent neoplasms. Higher physical activity (15-21 MET-h/wk) demonstrated a protective association for any (RR, 0.61; 95% CI, 0.53-0.71), solid organ (RR, 0.65; 95% CI, 0.52-0.83), CNS (RR, 0.50; 95% CI, 0.35-0.70), and skin (RR, 0.72; 95% CI, 0.60-0.86) subsequent neoplasms. BMI and physical activity were specifically associated with subsequent meningiomas and thyroid carcinomas, but not with breast or colorectal cancers, nor hematologic subsequent neoplasms.

Conclusions and relevance: Among childhood cancer survivors in this cohort study, obesity was associated with an increased risk for multiple subsequent neoplasm types, while higher physical activity was associated with reduced subsequent neoplasm risk. Lifestyle interventions should be considered in future subsequent neoplasm prevention research.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Mirzaei reported grants from the National Cancer Institute (NCI) during the conduct of the study. Dr Ness reported grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Im reported grants from NIH outside the submitted work. Dr Oeffinger reported being chief clinical officer of Maia Oncology outside the submitted work. Dr Armstrong reported grants from NIH to the Childhood Cancer Survivor Study during the conduct of the study. Dr Kadan-Lottick reported owning common stock in Procter & Gamble, Resmed Inc, Thermo Fisher Scientific Inc, AstraZeneca, BioMarin, Eli Lilly, and Intuitive Surgical. No other disclosures were reported.

References

    1. Dixon SB, Liu Q, Chow EJ, et al. Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet. 2023;401(10386):1447-1457. doi: 10.1016/S0140-6736(22)02471-0 - DOI - PMC - PubMed
    1. Armstrong GT, Chen Y, Yasui Y, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374(9):833-842. doi: 10.1056/NEJMoa1510795 - DOI - PMC - PubMed
    1. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008;100(19):1368-1379. doi: 10.1093/jnci/djn310 - DOI - PMC - PubMed
    1. Turcotte LM, Liu Q, Yasui Y, et al. Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer, 1970-2015. JAMA. 2017;317(8):814-824. doi: 10.1001/jama.2017.0693 - DOI - PMC - PubMed
    1. Turcotte LM, Neglia JP, Reulen RC, et al. Risk, risk factors, and surveillance of subsequent malignant neoplasms in survivors of childhood cancer: a review. J Clin Oncol. 2018;36(21):2145-2152. doi: 10.1200/JCO.2017.76.7764 - DOI - PMC - PubMed